Image Description

Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.

Introduction: Conventional sulfonylurea (SU) hypoglycemic agents stimulate insulin secretion from pancreatic β cells and improve glucose metabolism in type 2 diabetic patients. However, conventional SUs may promote the accumulation of visceral fat that causes multiple metabolic disorders leading to atherosclerosis, since they could cause delayed hyperinsulinemia via excessive insulin secretion especially under insulin-resistant condition  [1]  Glimepiride, a third-generation SU agent, has lesser insulin secretion action compared with conventional SUs such as glibenclamide. However, its hypoglycemic action is equivalent to them probably because it improves insulin sensitivity in subjects with and without diabetes  2 3 4  . Additionally, recent studies reported that glimepiride increased plasma adiponectin levels and decreased plasma TNF-α levels in type 2 diabetic subjects  [4 5]  . Therefore, it is suggested that glimepiride is more beneficial than conventional SUs for the prevention of atherosclerotic diseases. Indeed, in animal models…. […]

Artículo completo en: https://www.clinicalkey.com/#!/content/journal/1-s2.0-S0168822710006467

Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients




Ir a la barra de herramientas